Author

Charles Link

Observed names: C Link, C. Link, Charles E. Link, Link, Charles

Institution: NewLink Genetics (United States)

Observed institutions: Northwestern University, National Institutes of Health, Cleveland Clinic, Iowa State University, Medical College of Wisconsin, Augusta University, UnityPoint Health, Moffitt Cancer Center, Kameda Medical Center, NewLink Genetics (United States), Iowa Methodist Medical Center, National Cancer Institute, Human Gene Therapy Research Institute

OpenAlex ID: A5111961640

Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer

1994 · E. C. Kohn, G. Sarosy, et al. · JNCI Journal of the National Cancer Institute · 187

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

2014 · Hatem H. Soliman, Erica Jackson, et al. · Oncotarget · 174

PDF

A phase I study of indoximod in patients with advanced malignancies

2016 · Hatem H. Soliman, Susan E. Minton, et al. · Oncotarget · 145

PDF

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

2017 · D Gray Heppner, Tracy L Kemp, et al. · The Lancet Infectious Diseases · 117

Embryonic Stem Cells As an Alternate Marrow Donor Source

2004 · Richard K. Burt, Larissa Verda, et al. · The Journal of Experimental Medicine · 111

PDF

Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer

2020 · Veronica Mariotti, Hyo Han, et al. · JAMA Oncology · 51

Herpes simplex thymidine kinase gene–transduced donor lymphocyte infusions

2003 · Richard K Burt, William R Drobyski, et al. · Experimental Hematology · 44

PDF

Hematopoietic Mixed Chimerism Derived from Allogeneic Embryonic Stem Cells Prevents Autoimmune Diabetes Mellitus in NOD Mice

2007 · Larissa Verda, Duck An Kim, et al. · Stem Cells · 43

Pancreatic cancer: Update on immunotherapies and algenpantucel-L

2015 · Kinsey A. McCormick, Andrew L. Coveler, et al. · Human Vaccines & Immunotherapeutics · 42

PDF

Discovery of indoximod prodrugs and characterization of clinical candidate NLG802

2020 · Sanjeev Kumar, Firoz A. Jaipuri, et al. · European Journal of Medicinal Chemistry · 39

PDF

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1

2020 · Erik L. Brincks, James Adams, et al. · Oncotarget · 37

PDF

Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma

2017 · Yousef Zakharia, Robert McWilliams, et al. · Cancer Research · 37

A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors

2014 · Asha Nayak, Zhonglin Hao, et al. · Journal for ImmunoTherapy of Cancer · 33

PDF

A Phase I/II Study of Dose-Intense Paclitaxel with Cisplatin and Cyclophosphamide as Initial Therapy of Poor-Prognosis Advanced-Stage Epithelial Ovarian Cancer

1996 · Elise C. Kohn, Gisele A. Sarosy, et al. · Gynecologic Oncology · 30

Algenpantucel-L Immunotherapy in Pancreatic Adenocarcinoma

2016 · Andrew L Coveler, Gabriela R Rossi, et al. · Immunotherapy · 28

Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy

2006 · E Mitrofanova, R Unfer, et al. · Gene Therapy · 23

Rat Sodium Iodide Symporter for Radioiodide Therapy of Cancer

2004 · Elena Mitrofanova, Robert Unfer, et al. · Clinical Cancer Research · 21

Gene-Marked Autologous Hematopoietic Stem Cell Transplantation of Autoimmune Disease

2000 · Richard K. Burt, Malcolm Brenner, et al. · Journal of Clinical Immunology · 21

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma

2019 · Andrew W. Hahn, Charles Drake, et al. · The Oncologist · 17

PDF

346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors

2015 · A. Nayak, Z. Hao, et al. · European Journal of Cancer · 17

Sodium iodide symporter/radioactive iodine system has more efficient antitumor effect in three-dimensional spheroids.

2003 · Elena Mitrofanova, Christy Hagan, et al. · PubMed · 15

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

2018 · Ashkan Emadi, Vu H. Duong, et al. · Blood · 14

DNA Repair Defects Associated with Chromosomal Translocation Breaksite Regions

1994 · E J Beecham, G M Jones, et al. · Molecular and Cellular Biology · 14

514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma

2015 · Y. Zakharia, J. Drabick, et al. · European Journal of Cancer · 9

Actr-53. Interim Analysis of Phase 1b/2 Combination Study of the Ido Pathway Inhibitor Indoximod With Temozolomide for Adult Patients With Temozolomide-refractory Primary Malignant Brain Tumors

2016 · Yousef Zakharia, David Munn, et al. · Neuro-Oncology · 8

PDF

Works count: 39

Citation count: 1,315

H-index: 18

I10-index: 23